Drugs / Bortezomib
Bortezomib
also known as
Velcade · PS-341 · bortezomib (velcade) · Velcade TM · BTZ · NSC 681 239 · Velcade (Bortezomib) · -Velcade, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11 · +15 more
Small molecule targets MGMT, TGFB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 15 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | BORTEZOMIB | — | 2021-09-20 – 2022-12-09 | fda.gov ↗ |
| Label expansions (11) | US (FDA) | VELCADE | — | 2005-03-25 – 2019-04-25 | fda.gov ↗ |
| Approved | EU (EMA) | Velcade | — | 2004-04-26 | europa.eu ↗ |
| Approved | US (FDA) | VELCADE | — | 2003-05-13 | fda.gov ↗ |
Trials 746 · started per year
today
US approved 2003
EU approved 2004
2
3
20
13
23
45
63
71
47
54
41
58
38
27
28
16
23
19
13
12
21
19
11
15
19
16
5
13
1
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06142396 | Nov 2024 → Nov 2027 expected | kidney failure, plasma cell myeloma | Augusta University | Recruiting | No outcome recorded |
| Phase 0 | NCT04265872 | Oct 2020 → Dec 2026 expected | breast cancer | Baylor Research Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT02109861 | Jan 2014 → Dec 2015 | plasma cell myeloma | Henrik Gregersen | Unknown | No outcome recorded |
| Phase 0 | NCT01594242 | Jul 2012 → Mar 2015 | plasma cell myeloma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 0 | NCT01171092 | Sep 2010 → Jan 2013 | lymphoma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT00515138 | May 2007 → Nov 2011 | B-cell non-Hodgkin lymphoma | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT00437086 | Sep 2005 → Nov 2008 | leukemia, myeloproliferative neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 1146 trials · 1 met primary | ||||||
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07513129 | Jun 2026 → Dec 2029 expected | T-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06900647 | Jan 2025 → Jun 2026 overdue | breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT04912427 | Apr → Dec 2022 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04754945 | Apr 2021 → May 2027 expected | AL amyloidosis | Emory University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04392648 | Jun 2020 → Nov 2023 | refractory plasma cell neoplasm | Teva Branded Pharmaceutical Products R&D, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05982756 | Jan 2020 → Sep 2023 | acute myeloid leukemia | Zhongnan Hospital | Unknown | No outcome recorded |
| Show all 146 trials opens the full record — a long page | ||||||
| Phase 1/286 trials · 1 met primary | ||||||
| Phase 1/2 | NCT07601100 | Sep 2026 → Jul 2029 expected | plasma cell myeloma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07675174 | Jul 2026 → Jul 2030 expected | graft versus host disease | Northwell Health | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07008638 | Jul 2025 → Dec 2027 expected | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06572813 | Nov 2024 → Sep 2026 overdue | malignant pancreatic neoplasm | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06681922 | Sep 2024 → Oct 2027 expected | graft versus host disease | Northwell Health | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06246162 | Nov 2023 → Nov 2025 overdue | plasma cell myeloma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05895201 | Nov 2023 → Dec 2025 | acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myelomonocytic leukemia, disease related to hematopoietic stem cell transplant +1 | Indiana University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05422027 | Jul 2022 → Jun 2025 | plasma cell myeloma | Xia Zhongjun | Unknown | No outcome recorded |
| Phase 1/2 | NCT05289167 | Mar 2022 → Aug 2026 overdue | graft versus host disease | Northwell Health | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03643549 | Aug 2018 → Jun 2025 | glioblastoma | Haukeland University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03481556 | Apr 2018 → Feb 2022 | plasma cell myeloma | Oncopeptides AB | Terminated | No outcome recorded |
| Phase 1/2 | NCT03129828 | Mar 2017 → Nov 2024 | diffuse large B-cell lymphoma | Prof. Dr. Clemens Schmitt | Completed | No outcome recorded |
| Phase 1/2 | NCT02773030 | Oct 2016 → May 2024 overdue | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02971982 | Oct 2016 → Oct 2018 | — | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02553460 | Jan 2016 → May 2022 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02356458 | Aug 2015 → Mar 2021 | mantle cell lymphoma | Swiss Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02522572 | Aug 2015 → Sep 2020 | — | E. Steve Woodle | Unknown | No outcome recorded |
| Phase 1/2 | NCT02139397 | Jun 2014 → Jan 2024 | neuroblastoma | Giselle Sholler | Completed | No outcome recorded |
| Phase 1/2 | NCT02145715 | Jan 2013 → Jul 2015 | plasma cell myeloma | Prof Jamie Cavenagh | Unknown | Met primary |
| Phase 1/2 | NCT01534260 | Feb 2012 → Aug 2016 | acute myeloid leukemia | Hamid Sayar | Completed | No outcome recorded |
| Phase 1/2 | NCT01522872 | Feb 2012 → Sep 2016 | plasma cell myeloma | Threshold Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT01504477 | Dec 2011 → Feb 2014 | colorectal cancer | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01460420 | Nov 2011 → Jun 2017 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT01212952 | Sep 2011 → Aug 2017 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01408797 | Mar 2011 → Mar 2013 | uremia | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT01322776 | Mar 2011 → Oct 2013 | mantle cell lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01183949 | Nov 2010 → Dec 2014 | plasma cell myeloma | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01000285 | Sep 2010 → May 2014 | adult T-cell leukemia/lymphoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01177683 | Jul 2010 → Dec 2017 | plasma cell myeloma | Sherif Farag, MB, BS | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01460602 | May 2010 → Oct 2014 | follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Louisiana State University Health Sciences Center Shreveport | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01125293 | Apr 2010 → Dec 2013 | Waldenstrom macroglobulinemia | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01063907 | Mar 2010 → Nov 2013 | plasma cell myeloma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01034553 | Feb 2010 → Sep 2014 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT02353572 | Nov 2009 → Sep 2011 | smoldering plasma cell myeloma | University of Colorado, Denver | Terminated | No outcome recorded |
| Phase 1/2 | NCT00903968 | Jun 2009 → Jun 2016 | plasma cell myeloma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00923247 | Feb 2009 → Apr 2016 | medullary thyroid gland carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00849251 | Nov 2008 → Dec 2011 | plasma cell myeloma | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT00742625 | Sep 2008 → Jul 2010 | acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +5 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00750815 | Sep 2008 → Dec 2012 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00708292 | Jul 2008 → Jan 2011 | refractory plasma cell neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00719901 | Jul 2008 → Apr 2011 | plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00633594 | Jun 2008 → Apr 2015 | mantle cell lymphoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00724568 | May 2008 → Apr 2009 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00651781 | Apr 2008 → Jan 2013 | acute myeloid leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT00634179 | Feb 2008 → Nov 2015 | follicular lymphoma | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT00536575 | Nov 2007 → Feb 2010 | plasma cell myeloma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00372905 | Jul 2007 → Jun 2010 | lymphoma | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00483262 | May 2007 → Jan 2011 | plasma cell myeloma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00477412 | Apr 2007 → Oct 2020 | mantle cell lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00784823 | Jan 2007 → Dec 2013 | plasma cell myeloma | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 1/2 | NCT00426855 | Jan 2007 → Feb 2009 | non-Hodgkin lymphoma | Peter Moosmann | Completed | No outcome recorded |
| Phase 1/2 | NCT00411593 | Nov 2006 → May 2007 | lung cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00407303 | Oct 2006 → Mar 2009 | mantle cell lymphoma | Gemin X | Completed | No outcome recorded |
| Phase 1/2 | NCT00379574 | Sep 2006 → Jan 2011 | diffuse large B-cell lymphoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00378105 | Sep 2006 → Jul 2009 overdue | plasma cell myeloma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT00440726 | Aug 2006 → Feb 2011 | childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT00401011 | Aug 2006 → Dec 2010 | plasma cell myeloma | AEterna Zentaris | Completed | No outcome recorded |
| Phase 1/2 | NCT00369226 | Aug 2006 → Jul 2010 | hematopoietic and lymphoid cell neoplasm | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00411905 | Jun 2006 → Jul 2010 | myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Completed | No outcome recorded |
| Phase 1/2 | NCT00571493 | Apr 2006 → Nov 2014 | mantle cell lymphoma | University of Nebraska | Completed | No outcome recorded |
| Phase 1/2 | NCT00290706 | Apr 2006 → Feb 2011 | lymphoma | Northwestern University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00374699 | Apr 2006 → Sep 2009 | primary cutaneous T-cell lymphoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00313690 | Apr 2006 → ? | lung cancer | University of Southern California | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00334932 | Feb 2006 → Jan 2010 | plasma cell myeloma | Herbert Irving Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT00516100 | Jan 2006 → Jan 2010 | non-small cell lung carcinoma | Aptium Oncology Research Network | Unknown | No outcome recorded |
| Phase 1/2 | NCT00410423 | Jan 2006 → May 2013 | — | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT00295932 | Dec 2005 → Mar 2018 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00478075 | Sep 2005 → Nov 2007 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00184015 | Aug 2005 → Aug 2016 | renal cell carcinoma | University of Southern California | Unknown | No outcome recorded |
| Phase 1/2 | NCT00243035 | Aug 2005 → Feb 2007 | plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00361088 | Aug 2005 → Jun 2007 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00863369 | Jun 2005 → Aug 2016 | lymphoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00298766 | Jun 2005 → Jul 2009 | amyloidosis | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00389805 | Mar 2005 → Dec 2006 | lung cancer | University of California, Davis | Completed | No outcome recorded |
| Phase 1/2 | NCT00985907 | Oct 2004 → Oct 2008 | plasma cell myeloma | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00516191 | Oct 2004 → Oct 2010 | plasma cell myeloma | University of California, San Francisco | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00093756 | Sep 2004 → Jan 2012 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00084747 | Jun 2004 → Jan 2013 | plasma cell myeloma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00752518 | May 2004 → Jan 2006 | plasma cell myeloma, refractory malignant neoplasm | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1/2 | NCT00388635 | Apr 2004 → Jan 2007 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT00151320 | Jan 2004 → Apr 2010 | non-Hodgkin lymphoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1/2 | NCT00512798 | Jun 2003 → Jul 2006 | cancer, central nervous system neoplasm, melanoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00064610 | Dec 2002 → Dec 2004 | prostate neoplasm | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00237627 | May 2001 → Dec 2006 | breast cancer, leukemia, ovarian cancer, plasma cell neoplasm | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00995059 | — | plasma cell myeloma | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 2404 trials · 5 met primary · 16 missed | ||||||
| Phase 2 | NCT07652905 | Sep 2026 → Jun 2029 expected | plasma cell leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06348147 | Jul 2026 → May 2027 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT07227311 | Apr 2026 → Aug 2030 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT07085728 | Mar 2026 → Jan 2029 expected | plasma cell myeloma | Eastern Cooperative Oncology Group | Recruiting | No outcome recorded |
| Phase 2 | NCT07018050 | Sep 2025 → Nov 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06771180 | Jan → Dec 2025 overdue | monoclonal gammopathy | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06390319 | Dec 2024 → Dec 2027 expected | T-cell acute lymphoblastic leukemia, T-cell non-Hodgkin lymphoma, mixed phenotype acute leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05272826 | Dec 2024 → Mar 2028 expected | plasma cell myeloma | Canadian Myeloma Research Group | Recruiting | No outcome recorded |
| Phase 2 | NCT06656221 | Dec 2024 → Dec 2026 expected | mantle cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06574126 | Sep 2024 → Sep 2032 expected | smoldering plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Show all 404 trials opens the full record — a long page | ||||||
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT07732712 | Jan 2027 → Dec 2028 expected | plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07428369 | Jun 2026 → May 2038 | plasma cell myeloma | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT03759093 | Sep 2023 → Sep 2025 | plasma cell myeloma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2/3 | NCT05665140 | Feb 2023 → Aug 2027 expected | plasma cell myeloma | University Hopsital Schleswig Holstein Campus Lübeck | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03117751 | Mar 2017 → Sep 2026 overdue | lymphoblastic leukemia, acute, with lymphomatous features | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01805557 | Feb 2013 → Mar 2019 | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 2/3 | NCT00984828 | Aug 2009 → Jun 2016 | plasma cell myeloma | Shanghai Jiao Tong University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00861250 | Mar 2009 → Dec 2014 | plasma cell myeloma | Tampere University Hospital | Completed | No outcome recorded |
| Phase 357 trials · 17 met primary · 8 missed | ||||||
| Phase 3 | NCT07624513 | Aug 2026 → Oct 2033 expected | plasma cell myeloma | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07635511 | Jun 2026 → Jan 2029 expected | anti-HLA hyperimmunization, hematopoietic and lymphoid cell neoplasm, platelet disorder, undefined | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07222761 | Jan 2026 → May 2029 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06918002 | Jul 2025 → May 2036 expected | plasma cell myeloma | Intergroupe Francophone du Myelome | Recruiting | No outcome recorded |
| Phase 3 | NCT06158841 | May 2024 → Dec 2027 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT05572515 | Mar 2023 → Oct 2025 overdue | refractory plasma cell neoplasm | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 3 | NCT05558319 | Nov 2022 → Apr 2027 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT05083169 | Oct 2021 → Aug 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 3 | NCT04751877 | Jul 2021 → Jun 2024 overdue | plasma cell myeloma | Poitiers University Hospital | Active not recruiting | Met primary |
| Phase 3 | NCT04566328 | Feb 2021 → Dec 2027 expected | plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04181827 | Jun 2020 → May 2024 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 3 | NCT03729804 | May 2019 → Dec 2026 expected | plasma cell myeloma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT03643276 | Jul 2018 → Jul 2028 expected | childhood acute lymphoblastic leukemia | Martin Schrappe | Recruiting | No outcome recorded |
| Phase 3 | NCT03443570 | Mar 2018 → Mar 2020 | autoimmune thrombocytopenic purpura | Shandong University | Unknown | No outcome recorded |
| Phase 3 | NCT03110562 | May 2017 → Feb 2020 | plasma cell myeloma | Karyopharm Therapeutics Inc | Completed | Met primary |
| Phase 3 | NCT03345303 | Jan 2017 → Dec 2020 | intrahepatic cholangiocarcinoma | Zhengang Yuan | Unknown | No outcome recorded |
| Phase 3 | NCT02811978 | Sep 2016 → May 2018 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02489500 | Jun 2015 → Apr 2017 | AL amyloidosis | Boston Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02362165 | Apr 2015 → Apr 2018 | plasma cell myeloma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02197221 | Jan 2015 → Dec 2018 | plasma cell myeloma | University Hospital, Toulouse | Completed | Missed primary |
| Phase 3 | NCT02336386 | Dec 2014 → Dec 2016 | extramedullary plasmacytoma | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02112916 | Oct 2014 → Mar 2020 overdue | T-cell childhood acute lymphocytic leukemia, T-cell childhood lymphoblastic lymphoma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT01863550 | Dec 2013 → Dec 2026 expected | plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Active not recruiting | Missed primary |
| Phase 3 | NCT01788020 | Nov 2013 → Nov 2018 | Waldenstrom macroglobulinemia | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT01910987 | Apr 2013 → Feb 2016 | plasma cell myeloma | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT01685814 | May 2012 → Sep 2016 | — | Wuerzburg University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01539083 | Jan 2012 → Dec 2015 | plasma cell myeloma | Janssen Scientific Affairs, LLC | Completed | Missed primary |
| Phase 3 | NCT01371981 | Jul 2011 → Mar 2019 | myeloid sarcoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT01324596 | Apr 2011 → Apr 2015 | diffuse large B-cell lymphoma | University Hospital Southampton NHS Foundation Trust | Completed | Missed primary |
| Phase 3 | NCT01146834 | Mar 2011 → Feb 2019 | plasma cell myeloma | Weill Medical College of Cornell University | Completed | Missed primary |
| Phase 3 | NCT01277016 | Jan 2011 → Feb 2016 | AL amyloidosis | European Myeloma Network B.V. | Completed | Met primary |
| Phase 3 | NCT01078454 | Nov 2010 → Nov 2012 | light chain deposition disease, primary systemic amyloidosis | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01191060 | Oct 2010 → Nov 2018 | plasma cell myeloma | University Hospital, Toulouse | Completed | Met primary |
| Phase 3 | NCT01208662 | Sep 2010 → Feb 2022 overdue | plasma cell myeloma | Paul Richardson, MD | Active not recruiting | Met primary |
| Phase 3 | NCT01241708 | Apr 2010 → Jul 2023 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 3 | NCT01449344 | May 2009 → Dec 2018 | mantle cell lymphoma | Prof. Dr. M. Dreyling (co-chairman) | Unknown | Met primary |
| Phase 3 | NCT01530594 | Jan 2009 → Jan 2013 | plasma cell myeloma | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 3 | NCT00644228 | Jul 2008 → Nov 2015 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT00722566 | Jul 2008 → Aug 2010 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 3 | NCT00722137 | May 2008 → Jan 2014 | mantle cell lymphoma | Millennium Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 3 | NCT00416273 | Dec 2006 → May 2013 | plasma cell myeloma | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01801436 | Dec 2006 → Apr 2008 | plasma cell myeloma | Johnson & Johnson Taiwan Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00572169 | Nov 2006 → Aug 2027 expected | plasma cell myeloma | University of Arkansas | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00416208 | Oct 2006 → May 2013 | plasma cell myeloma | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00574080 | Jul 2006 → Mar 2011 | plasma cell myeloma | University of Arkansas | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01134484 | May 2006 → Aug 2008 | plasma cell myeloma | Michele Cavo | Unknown | Met primary |
| Phase 3 | NCT00312845 | Mar 2006 → Jun 2010 | non-Hodgkin lymphoma | Millennium Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 3 | NCT00417911 | Dec 2005 → May 2009 | plasma cell myeloma | Nordic Myeloma Study Group | Completed | Missed primary |
| Phase 3 | NCT00256776 | Jul 2005 → Dec 2013 | plasma cell myeloma | European Society for Blood and Marrow Transplantation | Terminated | No outcome recorded |
| Phase 3 | NCT00200681 | Jun 2005 → Jan 2008 | plasma cell myeloma | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00103506 | Dec 2004 → May 2014 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | Met primary |
| Phase 3 | NCT00111319 | Dec 2004 → Jul 2007 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 3 | NCT00093028 | Jan 2004 → Jan 2006 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT00048230 | Jun 2002 → Jul 2004 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00063726 | Apr 2002 → May 2005 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01386398 | — | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 420 trials | ||||||
| Phase 4 | NCT06015750 | Jul 2026 → Mar 2030 | hypophosphatasia | Alexion Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT06409702 | Jun 2024 → Nov 2027 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 4 | NCT05137860 | Dec 2021 → Dec 2022 | acute lymphoblastic leukemia, chemotherapy-induced toxicity | Hospital General de Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT05135442 | Dec 2021 → Nov 2023 | acquired thrombotic thrombocytopenic purpura | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04348006 | Mar 2020 → Jul 2021 | plasma cell myeloma | Al-Rasheed University College | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03908138 | Mar 2019 → Dec 2021 | plasma cell myeloma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03829371 | Jan 2019 → Jan 2027 expected | plasma cell myeloma | University of Turin, Italy | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02844322 | May 2016 → May 2022 | Waldenstrom macroglobulinemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 4 | NCT03844360 | Jan 2016 → Dec 2025 overdue | hematopoietic and lymphoid cell neoplasm | Wei Zhao | Recruiting | No outcome recorded |
| Phase 4 | NCT02268890 | Dec 2014 → Jul 2015 | plasma cell myeloma | Johnson & Johnson Taiwan Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02773550 | Jan 2014 → Jul 2018 | plasma cell myeloma | Basque Health Service | Terminated | No outcome recorded |
| Phase 4 | NCT01842074 | Mar 2013 → Mar 2017 | — | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 4 | NCT01169857 | Aug 2010 → Aug 2012 | lupus nephritis, proteinuria | The Rogosin Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02559154 | Jul 2010 → Oct 2018 | plasma cell myeloma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01103778 | Jul 2010 → Apr 2017 | IgA glomerulonephritis, chronic kidney disease | The Rogosin Institute | Completed | No outcome recorded |
| Phase 4 | NCT01249690 | Jun 2010 → Jun 2012 | plasma cell myeloma | Second Military Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT00908583 | May 2009 → Nov 2012 | anti-HLA hyperimmunization | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT00782821 | Sep 2008 → Feb 2013 | — | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT00652041 | Jan 2007 → Jan 2010 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00257114 | ? → Mar 2007 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT06192979 | Jan 2024 → Sep 2026 overdue | primary systemic amyloidosis | Jin Lu, MD | Recruiting | No outcome recorded |
| — | NCT06203145 | Jan 2024 → Nov 2025 | impaired renal function disease, plasma cell myeloma | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT05805891 | Dec 2023 → Jun 2025 | rheumatoid arthritis | Chinese SLE Treatment And Research Group | Unknown | No outcome recorded |
| — | NCT06215638 | Mar 2023 → Jun 2024 | rheumatoid arthritis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT05383547 | Aug 2022 → Dec 2023 | IgA glomerulonephritis, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis | Ruijin Hospital | Unknown | No outcome recorded |
| — | NCT03390387 | Nov 2015 → Nov 2020 | childhood acute lymphoblastic leukemia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02037256 | Jul 2011 → Jan 2015 | Burkitt lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +10 | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| — | NCT01383759 | Jun 2011 → Apr 2019 | amyloidosis, light and heavy chain deposition disease, light chain deposition disease | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT01273844 | Mar 2011 → May 2016 | AL amyloidosis | Zhi-Hong Liu, M.D. | Completed | No outcome recorded |
| — | NCT00772668 | Sep 2009 → Dec 2010 | follicular lymphoma, marginal zone lymphoma | University of Miami | Terminated | No outcome recorded Stop: Business |
| — | NCT00569868 | Aug 2005 → Jan 2008 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| — | NCT00789256 | Sep 2004 → Dec 2008 | acute myeloid leukemia, myelodysplastic syndrome | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT00135187 | Jul 2004 → Aug 2006 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase not stated4 trials | ||||||
| — | NCT00799539 | — | plasma cell myeloma | Janssen-Ortho Inc., Canada | No longer available | No outcome recorded |
| — | NCT03763370 | — | plasma cell myeloma | GlaxoSmithKline | Available | No outcome recorded |
| — | NCT01250808 | — | plasma cell myeloma | Peking University | Available | No outcome recorded |
| — | NCT00063791 | — | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | No longer available | No outcome recorded |
| Comparator or background therapy213 trials | ||||||
| Phase 0 | NCT04776850 Background | Dec 2020 → Dec 2022 | beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT07609706 Background | Oct 2026 → Aug 2031 expected | plasma cell myeloma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05052970 Background | Oct 2021 → Apr 2023 | refractory plasma cell neoplasm | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04956302 Background | Sep 2021 → Jun 2022 | plasma cell myeloma | Abdullah Khan | Terminated | No outcome recorded |
| Show all 213 trials opens the full record — a long page | ||||||
Press releases naming this drug 29 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 969 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bortezomib | “Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone...” NCT01460602 ↗894“The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab,...” NCT07099391 ↗ “Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m(2) orally on days 1,...” PMID 19225538 ↗ Feb 2009 “The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment...” NCT07709715 ↗ “Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide,...” NCT07149857 ↗ “The purpose of this study is to determine whether Bortezomib is effective in the treatment of patients with non-small-cell lung cancer who have not received any prior...” NCT00346645 ↗ “Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in...” NCT02573935 ↗ “A phase I study was conducted to determine the tolerability and the maximum tolerated dose of bortezomib when administered in combination with IFN-α-2b to patients with...” PMID 24316557 ↗ Jan 2014 “PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma” NCT00319865 ↗ “Bortezomib (VELCADE), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma.” PMID 20012045 ↗ Dec 2009 “Phase II Clinical Study of Daratumumab Combined With Bortezomib, Lenalidomide and Dexamethasone (DVRd) in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma” NCT06158269 ↗ |
| Known as | -Velcade, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00740415 ↗ |
| Known as | Bortezomib (PS-341) | “Bortezomib (PS-341)” NCT03016988 ↗ |
| Known as | bortezomib (velcade) | “Bortezomib (Velcade ®)” NCT01860170 ↗9“Bortezomib (VELCADE®)” NCT01206205 ↗ “Bortézomib (VELCADE®)” NCT01191060 ↗ “bortezomib (velcade)” NCT00580320 ↗ “Bortezomib (Velcade)” NCT00250926 ↗ “Bortezomib (velcade)” NCT01720875 ↗ “Bortezomib (Velcade)” NCT00691704 ↗ “bortezomib (Velcade)” NCT00837174 ↗ “Bortezomib: Velcade” NCT01449344 ↗ “Bortezomib=Velcade” NCT00516191 ↗ |
| Known as | Bortezomib accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib fresenius kabi | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib hospira | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib Injection | “Bortezomib Injection, a kind of chemotherapy drug” NCT06572813 ↗ |
| Known as | Bortezomib or Velcade | “Bortezomib or Velcade” NCT00793650 ↗ |
| Known as | Bortezomib sun | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | bortizomib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02577783 ↗ |
| Known as | Botezomib | “Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability” NCT00257114 ↗ |
| Known as | BTZ | “We previously reported that administration of bortezomib (BTZ) after 4 days of granulocyte colony-stimulating factor (G-CSF) significantly augments mobilization in mice.” PMID 31358485 ↗ May 20194“BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).” NCT02188368 ↗ “Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).” NCT02290431 ↗ “pretreatment with bortezomib (BTZ) 48 hours prior to TMZ to deplete MGMT levels would be safe and tolerated” PMID 32578964 ↗ Jun 2020 “DARA in combination with bortezomib (BTZ) and low-dose dex (DVd)” NCT03651128 ↗ |
| Known as | JNJ-26866138 | “A Phase I/II Study of JNJ-26866138 (Bortezomib) in Japanese Patients With Relapsed or Refractory Multiple Myeloma” NCT00752518 ↗ |
| Known as | LDP-341 | “VELCADE™ (bortezomib) for Injection, formerly known as MLN341, LDP-341 and PS-341.” NCT00063726 ↗ |
| Known as | MLN341 | “VELCADE™ (bortezomib) for Injection, formerly known as MLN341, LDP-341 and PS-341.” NCT00063726 ↗ |
| Known as | NSC 681 239 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗4“A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide And Low Dose...” NCT00644228 ↗ “Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms” NCT00082784 ↗ “Phase I Trial of Bortezomib (NSC 681239, IND#58443) and Carboplatin in Recurrent or Progressive Epithelial Ovarian Cancer or Primary Peritoneal Cancer” NCT00028912 ↗ “A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer” NCT00028639 ↗ |
| Known as | PS-341 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗46“BACKGROUND: Based on evidence of activity in epithelial tumors in preclinical and Phase I studies, its novel mechanism of action, and its tolerability we undertook a study of...” PMID 16983508 ↗ Sep 2006 “The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered...” NCT00200382 ↗ “Bortezomib (PS-341, Velcade ), a proteasome inhibitor, has been reported to have several putative mechanisms of action and it is likely that its toxicity is mediated by...” NCT00923247 ↗ “Bortezomib (also called Velcade or PS-341) has been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, but has not been approved for the...” NCT00184015 ↗ “A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute...” NCT00382954 ↗ “PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma” NCT00319865 ↗ “Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not exceeding 3.0 mg (equivalent to 1.75 mg/m2), repeated on D1 and D4 every other week.” PMID 16135477 ↗ Sep 2005 “Two new drugs BORTEZOMIB (Velcade®, PS-341) and REVLIMID (CC-5013) have been shown in recent studies to be effective in patients with advanced multiple myeloma.” NCT00093028 ↗ “Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms” NCT00082784 ↗ “A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.” PMID 20574790 ↗ Jun 2010 |
| Known as | Velcade | “A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or...” NCT00515138 ↗147“The primary objective of this research study is to determine the maximum tolerated dose (MTD) of Ruxolitinib (Jakafi) in combination with standard dose Bortezomib (Velcade) in...” NCT02613598 ↗ “The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the...” NCT01063907 ↗ “Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma...” NCT00389701 ↗ “Subjects are invited to participate in this study that will examine the use of three drugs called Sorafenib (Nexavar), Vorinostat (Zolinza) and Bortezomib (Velcade) for...” NCT01534260 ↗ “The purpose of this study is to allow patients to receive VELCADE™ (bortezomib) for Injection who experienced progressive disease(PD) while receiving high-dose dexamethasone...” NCT00063726 ↗ “Bortezomib (also called Velcade or PS-341) has been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, but has not been approved for the...” NCT00184015 ↗ “A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute...” NCT00382954 ↗ “MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative...” NCT00564200 ↗ “PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma” NCT00319865 ↗ “A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse.” NCT01910987 ↗ |
| Known as | Velcade (Bortezomib) | “Velcade (Bortezomib)” NCT02237261 ↗3“Velcade (bortezomib)” NCT01554852 ↗ “Velcade (bortezomib)” NCT00516100 ↗ “Velcade : Bortezomib” NCT01045681 ↗ |
| Known as | Velcade TM | “Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in...” NCT01386398 ↗6“VTD is a combination of drugs consisting of VelcadeTM (also known as bortezomib), Thalidomide, and Dexamethasone.” NCT00577668 ↗ “Bortezomib, or Velcade(TM), is given for a few seconds by a rapid push through a needle into the vein.” NCT00092222 ↗ “VELCADE TM (bortezomib) for Injection, or PS-341” NCT00051987 ↗ “VELCADE TM (bortezomib) for Injection, or PS-341” NCT00064636 ↗ “VELCADE TM (bortezomib) for Injection” NCT00064610 ↗ “VELCADE TM (bortezomib) for Injection” NCT00063713 ↗ |
| Known as | Velcade(R) | “Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles” NCT00777738 ↗ |
| Known as | Velcade-drug | “PS-341 (Velcade-drug)” NCT00200382 ↗ |
| Action | Inhibit | “Proteasome inhibition with bortezomib (PS-341)” PMID 16135477 ↗ Sep 2005 |
| Modality | Small molecule | “Bortezomib (Velcade) is a modified dipeptidyl boronic acid” NCT00374699 ↗ |
| Route | Intravenous | “Patients receive PS-341 IV on days 1 and 4.” NCT00004002 ↗ |
| Target | TGFB1 | “Bortezomib, an FDA approved proteasomal inhibitor inhibits TGF-b1 signaling” NCT01163786 ↗ |